Balmus, Gabriel http://orcid.org/0000-0003-2872-4468
Pilger, Domenic http://orcid.org/0000-0001-7339-0685
Coates, Julia
Demir, Mukerrem
Sczaniecka-Clift, Matylda
Barros, Ana C.
Woods, Michael
Fu, Beiyuan
Yang, Fengtang http://orcid.org/0000-0002-3573-2354
Chen, Elisabeth http://orcid.org/0000-0003-2129-7985
Ostermaier, Matthias
Stankovic, Tatjana
Ponstingl, Hannes http://orcid.org/0000-0001-7573-1703
Herzog, Mareike
Yusa, Kosuke
Martinez, Francisco Munoz
Durant, Stephen T. http://orcid.org/0000-0003-4209-7499
Galanty, Yaron http://orcid.org/0000-0001-7167-9004
Beli, Petra http://orcid.org/0000-0001-9507-9820
Adams, David J.
Bradley, Allan
Metzakopian, Emmanouil
Forment, Josep V. http://orcid.org/0000-0002-7797-2583
Jackson, Stephen P. http://orcid.org/0000-0001-9317-7937
Article History
Received: 14 August 2018
Accepted: 15 November 2018
First Online: 8 January 2019
Competing interests
: J.V.F. and S.T.D. are both full-time employees and shareholders of AstraZeneca. S.P.J. is a Director of Mission Therapeutics Ltd., and is founder and Director of Adrestia Therapeutics Ltd. G.B. is a co-founder and consultant for Adrestia Therapeutics Ltd. The remaining authors declare no competing interests.